Page 16 - ஆரோக்கியம் காப்பீடு திட்டங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Medicare to weigh nationwide coverage rules for Biogen Alzheimer s drug Responding to calls from insurers and patient groups, CMS will consider whether a single policy is necessary for Aduhelm. Published July 12, 2021 Permission granted by Biogen The Centers for Medicare and Medicaid Services will formally consider whether to adopt nationwide rules for coverage of Biogen s new Alzheimer s drug Aduhelm, announcing Monday the opening of a determination process that could shape how millions of Americans are able to access the controversial treatment. Patient advocacy groups and insurers have urged CMS to set a single Medicare policy on coverage of Aduhelm, which Biogen priced at an average cost of $56,000 per year. Experts fear the drug the first new Alzheimer s treatment approved in nearly two decades and the first ever meant to treat the disease s underlying cause could add tens of billions of dollars to

United statesEli lillyAmerica health insuranceCenters for medicareAlzheimer associationDrug administrationMedicaid servicesChiquita brooks lasureHealth insurance plansஒன்றுபட்டது மாநிலங்களில்எலி லில்லிஅமெரிக்கா ஆரோக்கியம் காப்பீடுமையங்கள் க்கு மருத்துவமுதுமறதி சங்கம்மருத்துவ உதவி சேவைகள்ஆரோக்கியம் காப்பீடு திட்டங்கள்